Ramez N. Eskander, MD

Ramez N. Eskander, MD, discusses additional targetable biomarkers that could be addressed in a similar combination as what was seen in the phase 3 NRG-GY018/KEYNOTE-868 trial with standard of care chemotherapy.

Discover the potential of tisotumab vedotin combinations and emerging treatment strategies in the evolving landscape of cervical cancer management.

Ramez N. Eskander, MD, discusses the importance of understanding and managing treatment-related adverse events, including ocular side effects, bleeding, and neuropathy, associated with the innovative therapy tisotumab vedotin in cervical cancer patients.

Perspectives on the breakthrough antibody drug conjugate, tisotumab vedotin, its mechanism of action, and the significant clinical benefits it offers to patients with recurrent or metastatic cervical cancer, leading to FDA approval and promising results in a confirmatory trial.

Ramez N. Eskander, MD, explores evolving treatment options, including immunotherapy and antibody drug conjugates, in recurrent cervical cancer, highlighting the importance of biomarkers and clinical trials in this dynamic landscape.

An overview of the remarkable evolution in the treatment landscape for metastatic and recurrent cervical cancer patients, shaped by pivotal clinical trials and the integration of immunotherapy, resulting in significantly improved clinical outcomes.

A key opinion leader explores the significance of biomarkers, including PD-L1 CPS score, TMB, MSI, and HER2, in shaping advanced treatment strategies for cervical cancer patients, emphasizing personalized care and clinical trial opportunities.

Expert insight into the pivotal role of HPV vaccines, evolving vaccination strategies, and advanced screening methods in cervical cancer prevention and management on a global scale.

Ramez N. Eskander, MD, discusses a challenging cervical cancer case, highlighting treatment advances and decision-making in recurrent and metastatic settings.

Ramez N. Eskander, MD, explains the rationale for treating a 71-year-old woman with ovarian cancer with the PARP inhibitor rucaparib upon relapse.

Ramez Eskander, MD, presents the case of a 68-year-old woman with stage IV ovarian cancer, and discusses the management approach for this patient and similar cases.

Ramez N. Eskander, MD, discusses the current outlook for the frontline treatment landscape in ovarian cancer.